Clinical Trials
28 trialsNCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT03043391 2024-04-08
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Phase 1 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT05363826 2023-04-13
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Photolitec LLC
Phase 1 Recruiting
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT00031083 2020-11-17
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
Phase 1 Completed
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT02197169 2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1 Completed
NCT01870726 2018-05-30
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis
Phase 1/2 Terminated
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00087451 2015-08-19
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01124539 2014-12-09
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Arno Therapeutics
Phase 2 Unknown
NCT00960492 2014-09-22
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Exelixis
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00107237 2013-06-12
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Novartis
Phase 1/2 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed
NCT00003293 2012-09-11
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed
NCT00004200 2012-08-08
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Pfizer
Phase 2 Completed
NCT00114309 2009-04-03
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
TransMolecular
Phase 2 Unknown
NCT00157703 2008-12-16
G207 Followed by Radiation Therapy in Malignant Glioma
MediGene
Phase 1 Completed